Stage III Cutaneous Melanoma AJCC v7 Terminated Phase 1 Trials for Trametinib (DB08911)

IndicationStatusPhase
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01940809
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTreatment